Immunome Reports Quarterly Earnings, Falls Short of Expectations

Immunome (NASDAQ:IMNM) released its quarterly earnings report on Wednesday, revealing a loss of ($0.84) earnings per share (EPS) for the period. This result was below the analysts' consensus estimate, which anticipated a loss of ($0.68) EPS, marking a miss of ($0.16).

Financial Performance and Metrics

In terms of financial health, Immunome reported a negative return on equity of 48.63% and a staggering negative net margin of 3,014.59%. These figures highlight challenges faced by the company in generating profits.

Immunome Stock Movement

During midday trading on Wednesday, Immunome’s stock saw an increase of $0.21, reaching $8.57. A total of 522,477 shares were exchanged, while the average trading volume is around 810,302 shares. The stock has a 52-week range, with a low of $8.34 and a high of $26.70. Currently, the firm holds a market capitalization of approximately $683.69 million, with a price-to-earnings ratio of -1.06 and a beta of 1.93. The stock's 50-day simple moving average stands at $9.89, while the 200-day simple moving average is at $11.66.

Insider Transactions

In addition to the earnings report, recent insider trading activities have also drawn attention. CEO Clay B. Siegall purchased 150,000 shares of Immunome on Friday, January 31st, at an average price of $7.75 per share. This acquisition totaled $1,162,500, and after this transaction, Siegall holds 669,636 shares valued close to $5.19 million, indicating a significant 28.87% increase in his holdings. As of now, corporate insiders own about 8.60% of the company’s stock.

Analysts and Price Targets

Several analysts have issued recent reports on Immunome, with Lifesci Capital initiating coverage with an 'outperform' rating and a price target of $20.00. Additionally, Wedbush reaffirmed its 'outperform' rating with a projected price target of $33.00. Overall, six analysts have rated Immunome with a buy recommendation, leading to a consensus rating of 'Buy' and an average price target of $27.17, according to MarketBeat.com.

Overview of Immunome, Inc.

Immunome, Inc. is a biotechnology company focused on developing targeted cancer therapies. Its leading clinical asset is AL102, an investigational gamma secretase inhibitor undergoing evaluation in a Phase 3 trial aimed at treating desmoid tumors. The company also has preclinical assets such as IM-1021, IM-3050, and IM-4320, which include various therapies related to receptor tyrosine kinase-like orphan receptor 1, radioligand therapy, and anti-IL-38 immunotherapy candidates.

Investment Considerations

Before considering an investment in Immunome, potential investors may wish to review its current performance alongside other options in the market. Notably, some analysts have highlighted five stocks with stronger recommendations compared to Immunome, which may be worth exploring.

Immunome, Earnings, Stocks